Rajeev Ronanki, CEO of Lyric and former Elevance Health executive, unpacks what the FDA’s AI initiative—Elsa—really means for drug innovation and regulation. Rajeev outlines how the agency can use data it already has to drive smarter, faster decisions. He draws powerful parallels to autonomous vehicles and urges the FDA to embrace AI while maintaining scientific rigor.
